David R. Greeley
David R. Greeley publishes mostly in Neurology, Psychiatry and Mental health and Physiology, on topics such as Neurological disorders and treatments, Parkinson's Disease Mechanisms and Treatments and Botulinum Toxin and Related Neurological Disorders.
- World rank
- #2,798,618 of 7,710,434 ranked researchers
- Rank in United States
- #812,123 of 1,627,098
- Works
- 21
- Citations
- 3.4k
- Citations per work
- 163.3
What does David R. Greeley research?
David R. Greeley's work is mostly in Medicine (62%), Biochemistry, Genetics and Molecular Biology (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1362.0%
- Medicine1362.0%
- Everything else732.8%
- Life Sciences15.2%
- 1Neurology38% of their works
- 2Psychiatry and Mental health10% of their works
- 3Physiology5% of their works
- 4Molecular Biology5% of their works
- 5Oncology5% of their works
- 6Surgery3% of their works
Research topics
- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Phosphodiesterase function and regulation
- Parkinson's Disease and Spinal Disorders
- Cancer Treatment and Pharmacology
Which keywords describe David R. Greeley's research?
The keywords of their largest research topics: Parkinson's Disease, Neurological Disorders, Deep Brain Stimulation, Neurodegeneration, Oxidative Stress, Basal Ganglia, Subthalamic Nucleus and a-Synuclein.
- Taxanes
- Cyclic Nucleotide Phosphodiesterases
- Camptocormia
- Amyloid Hypothesis
- Mild Cognitive Impairment
- Alzheimer's Disease
- Dopaminergic Neurons
- Basal Ganglia
- Neurodegeneration
- Neurological Disorders
- Parkinson's Disease
- Deep Brain Stimulation
- Oxidative Stress
- Subthalamic Nucleus
- a-Synuclein
- Botulinum Toxin
- Neurotoxins
- Tau Pathology
- Chemotherapy-Induced Peripheral Neuropathy
- Dropped Head Syndrome
- cAMP Signaling
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Parkinson's Disease173 topics
- Neurological Disorders153 topics
- Deep Brain Stimulation102 topics
- Neurodegeneration102 topics
- Oxidative Stress102 topics
- Basal Ganglia81 topic
- Subthalamic Nucleus81 topic
- Dopaminergic Neurons71 topic
- a-Synuclein71 topic
- Alzheimer's Disease51 topic
- Botulinum Toxin51 topic
- Mild Cognitive Impairment51 topic
- Neurotoxins51 topic
- Amyloid Hypothesis31 topic
- Tau Pathology31 topic
- Camptocormia21 topic
- Chemotherapy-Induced Peripheral Neuropathy21 topic
- Cyclic Nucleotide Phosphodiesterases21 topic
- Dropped Head Syndrome21 topic
- Taxanes21 topic
- cAMP Signaling21 topic
Where does David R. Greeley work?
David R. Greeley's main affiliation in the publication record is Arthritis Northwest, United States.
How many publications and citations does David R. Greeley have?
OpenAlex counts 21 works and 3,430 citations for David R. Greeley, an h-index of 10, ranking #2,798,618 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about David R. Greeley. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.